Background: Fecal incontinence is a debilitating and highly prevalent problem among multiple sclerosis patients. Conservative therapies often fail to provide benefit. Posterior tibial nerve stimulation is a minimally invasive neuromodulatory therapy with proven efficacy for fecal incontinence in non-neurological settings.
INTRODUCTION
Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system, which causes progressive disability as demyelinating lesions accumulate in the brain and spinal cord. The disease typically has onset in young adulthood, has a predilection for females and occurs most often in Western countries, where the prevalence is at least 100 per 100,000 persons (1) .
Abnormalities of bowel function, including both constipation and fecal incontinence (FI), are common in MS. FI is present in up to 50% of these patients, and frequently occurs along with constipation (2, 3) . The pathophysiology of FI in MS may be related to direct effects of the condition such as central nervous system lesions impairing afferent and efferent pathways to the bowel, impaired anorectal sensation or behavioral changes affecting toileting habits. Other global features of MS such as striated muscle weakness and impaired mobility may also play a role (2) .
Management of FI in MS remains empirical and is mostly similar to that offered to non-neurogenic FI patients. Conservative therapies are used first-line; these include dietary advice, stool bulking fiber supplements, anal plugs for containment and the use of antimotility drugs such as loperamide. Our group has previously published on the efficacy of biofeedback and transanal irrigation in MS (4, 5) , but there is certainly a need for additional treatment options.
Posterior tibial nerve stimulation (PTNS) is a form of neuromodulation that has gained acceptance in the treatment of FI. A number of published studies have now demonstrated significant benefits from PTNS, however, these studies either excluded patients with MS or included very few (6, 7) ; hence it is unclear whether the findings can be extrapolated to the MS cohort. The mechanism of action of PTNS has not been fully elucidated, however, modulation of central pathways regulating colorectal motility and afferent sensory perception probably plays a part (8, 9) . If so, then it is conceivable that PTNS would be of benefit in this patient group. The aim of this study is to determine whether PTNS is effective in the treatment of FI in MS patients, and also to identify factors that predict treatment success as a pilot to plan a definitive randomized study.
MATERIALS AND METHODS

Study Design
A retrospective analysis of prospectively collected data was performed. MS patients with FI were first treated with PTNS at University College London Hospital, a tertiary referral centre, in 2012; we included consecutive patients who underwent this treatment during a three-year period following this (i.e., between 2012 and 2015). Baseline characteristics including age, duration and type of MS, and obstetric history were ascertained. All subjects had previously failed conservative therapies including biofeedback, and had undergone anorectal physiology investigations and an endoanal ultrasound. Failure to regularly attend the scheduled PTNS sessions was the sole exclusion criterion.
Posterior Tibial Nerve Stimulation
A protocol was used to provide a standardized procedure for the administration of PTNS to all study subjects (7, 10) . A 34 gauge needle was inserted 5 cm cephalad to medial malleolus and 2 cm posterior to tibia at a 608 angle, with a base electrode placed on the ipsilateral leg, with the patient lying supine or sitting in a chair (Fig. 1) . Both electrodes were then connected to the neurostimulator device (Urgent PC, Cogentix, Manchester, UK). Correct needle placement was confirmed in all subjects by motor and/or sensory response (flexion of big toe, fanning of all toes or tingling sensation of foot extending to all toes). A suitable neurostimulation setting was then chosen whereby the patient was able to comfortably receive 30 min of therapy; subjects received neuromodulation therapy at this optimal setting on a weekly basis for a minimum of eight weeks. If no response was obtained at eight weeks then therapy was ceased, as per our unit policy given absence of subsequent treatment response in our experience. Those who had exhibited some response during the first eight weeks continued therapy so that they completed 12 weeks in total (11) .
Anorectal Physiology Testing
Testing was performed using standardized methods that have been described elsewhere in detail; our previously reported normal values are used (4, 12, 13 ). An 8-channel water perfused catheter (Ardmore Healthcare, Ltd, External Diameter 3.9 mm with Mui pump, using Medical Measurement System software) was used to determine anal resting and squeeze pressures by the "station pullthrough" method. Rectal sensitivity to mechanical sensation was measured by inflation of a latex balloon placed 6 cm above the anal verge, with the threshold volume, urge volume (where urge to defecate is first perceived) and maximal tolerated volume all being ascertained. Last, anal and rectal sensitivity to electrical sensitivity were measured using a bipolar electrode catheter (Gaeltec, Ltd, using Medical Measurement System software). Electrical stimulation was applied to the anus (at 1 cm above the anal verge), followed by the rectum (at 6 cm above the anal verge). In the anus, stimulation was applied at 5 Hz with a pulse width of 0.1 ms, and the current gradually increased to 20 mA until the patient first reported sensation. The same process was repeated in the rectum using 10 Hz, pulse width 0.5 ms, and gradual increase of current up to 50 mA (14) .
Endoanal Ultrasound
Ultrasound examination was performed by experienced radiologists in the established fashion (15, 16) . Briefly, the endoanal ultrasound probe (BK Medical Profocus, Herley, Denmark) was inserted into the rectum with the patient in the left lateral decubitus position. Contiguous images of the anal sphincter were captured, from its proximal extent at the puborectalis muscle and proceeding caudally. Hyper-or hypoechoic disruptions in the internal and/or external anal sphincters of at least 5 mm thickness were noted.
Outcomes
At baseline and immediately following completion of PTNS therapy, a number of validated measures of symptom severity in patients with FI were administered and the results collected. These included:
• The Wexner Incontinence questionnaire is a validated and reproducible measure for assessing severity of fecal incontinence; it does so on a scale of 0-20, with 0 representing the absence of any symptoms and 20 corresponding to the greatest severity of symptoms (17).
• The Rockwood score is a reliable and valid quality of life measure specific to fecal incontinence (18) . It assigns a score for each of four domains, lifestyle, coping, depression, and embarrassment. These are scored between 1 and 5, with 1 indicating lower functional status or quality of life.
• Two visual analogue scales (VASs) were used, for bowel and bladder symptoms, respectively. Each produced a score between 0 and 100, with a higher score corresponding to a greater severity of symptoms within that system. • The Bristol Stool Form Scale has not been validated for use specifically in FI, but is a valid and reliable seven-point scale used extensively in clinical and research settings for measurement of stool form in both healthy patients and those with diarrhea (19) . Type 1 We chose to analyze all of the patients as a single cohort. Outcome was assessed on the basis of response to treatment. Subjects were classified as responders or nonresponders to the treatment based on reduction in Wexner score to below 10 or by halving of the baseline score, as has been used in previous studies (20) (21) (22) . Characteristics of responders and nonresponders were then compared in order to identify factors potentially predictive of response to therapy.
Statistics
Statistical analysis was undertaken using Microsoft Excel and STATA. For normally distributed data, paired two-tailed t-tests were used. For nonparametric data Mann-Whitney U tests were used. For parametric data, Pearson correlation was used. Chi-squared and its other variants (i.e., Fisher tests) analyzed nonparametric data. A P value of 0.05 was considered significant.
RESULTS
Demographics
A total of 33 patients (25 female) fulfilled the criteria and were included in the study. The median age was 48 years (interquartile range [IQR]: 41-58 years). Median time since diagnosis of MS was 14 years (9-26 years), while median duration of FI symptoms was 10 years (6-13 years). Twenty-two patients (67%) had relapsingremitting MS, 3 (9%) had primary progressive MS, and 8 (24%) had secondary progressive MS. Anal canal length was within the normal range (between 2 and 4.5 cm) in 32 out of 33 patients.
The vast majority (29 patients, 88%) gave a history of urge FI; of these nine (27%) also described passive FI along with urge symptoms, while only four patients (12%) had purely passive FI. Three patients were already taking loperamide and glycerine suppositories, two were taking an osmotic laxative, one was taking a stimulant laxative, and one was taking hyoscine butylbromide; these were continued during the study period. Otherwise, the majority of patients (79%) were not concurrently taking any laxatives or drugs affecting gastrointestinal motility.
Patients were followed until the end of their treatment duration. Twenty-six patients (79%) were classified as responders by the predetermined Wexner score criteria, while 7 (21%) were nonresponders. In magnitude, mean Wexner score among responders reduced from 13.5 6 3.8 at baseline to 7.0 6 2.8 after PTNS therapy, whereas in nonresponders it rose slightly from 13.4 6 3.9 to 13.9 6 3.1 (Table 1) . There was no significant difference in age between responders and nonresponders (P 5 0.36).
Change in Symptom Outcome Measures in Responders and Nonresponders
A comparison of VAS, Rockwood and Bristol Stool scores preand post-PTNS is displayed in Table 2 . At baseline responders tended to be more disabled as measured by most of these outcome scores, being significantly more so by the Rockwood depression subscore. Responders demonstrated improvement in at least some objective outcome measures related to their FI; conversely, nonresponders did not demonstrate any significant improvement in any parameters, and in fact exhibited worsening in most of these outcomes. Responders demonstrated an improvement in the Rockwood depression score (2.7 6 0.8 pre to 3.1 6 0.9 post-therapy, P 5 0.01). In addition, we observed that responders exhibited an improvement in stool consistency following treatment, as demonstrated by change in median Bristol Stool Form Scale score (from 5 to 4, P 5 0.02). When the magnitude of improvement in all parameters was compared between responders and nonresponders, a trend toward greater improvement among responders was seen, though this only reached significance for the Rockwood depression score and the Bristol Stool Form score. 
Factors Associated With Treatment Success
Relapsing remitting MS subtype was associated with statistically greater likelihood of treatment response (P < 0.05), with 95% in this subset reporting success in comparison to those with primary progressive (67%) and secondary progressive MS (50%).
Among the 25 female patients, 16 had had vaginal deliveries. Of these, the number of vaginal deliveries was not related to treatment outcome (P 5 0.61).
The majority of the cohort had ultrasonographically intact external and internal anal sphincters; with only 5 (16%) demonstrating defects in sphincter integrity or sphincter atrophy. Sphincter integrity was not associated with treatment outcome (P 5 0.94).
Comparing baseline anorectal physiology parameters between responders and nonresponders, we found no statistically significant difference in resting and squeeze pressures, sensitivity to balloon distension or electrosensitivity between responders and nonresponders (Table 3) .
DISCUSSION
The feasibility of PTNS for FI in two spinal injury patients has been previously described (23) , but this study is the first to examine the efficacy of PTNS for FI among cohort patients with MS. We report a high rate of treatment success in a carefully defined population. Improvement was seen in 81% of subjects who underwent therapy as defined by improvement in Wexner score. This is a higher rate of success than has been previously described in studies of PTNS for FI (6) , where those with neurologic causes were generally excluded or limited to one or two patients among the entire cohort (24) . The improvement in Wexner score in responders was accompanied by a trend to improvement in the bowel VAS score and quality of life scores, though this only reached significance for the depression subscore. These improvements are in keeping with the already recognized correlation between Wexner score and quality of life (25) .
We observed that patients who responded to PTNS tended to be more disabled at baseline, in terms of not only bowel symptoms but also quality of life. It may be that part of the reason for lack of benefit perceived in nonresponders was due to lesser severity of symptoms at baseline. Alternatively, patients with greater disability may have benefited from the intensive clinical follow-up that is part of PTNS therapy.
The only factor we found that was predictive of treatment success was relapsing remitting MS subtype. While response rates for all subtypes were good, rates were significantly lower for secondary and primary progressive subtypes. Given current consensus on the clinical course of MS subtypes, our findings could be explained by a greater neurological disease burden in the progressive subtypes, meaning that any form of therapy is less likely to succeed (26, 27) ; however, it must be noted that the number of patients with secondary and primary progressive MS was far lower than the number with relapsing-remitting.
Other factors we examined were not predictive of treatment success, with our findings being largely in keeping with those reported in previous studies of PTNS in non-neurogenic FI. Sphincter integrity was unrelated to treatment outcome, as has been demonstrated previously in non-neurogenic FI (28) . No anorectal physiology parameter was associated with treatment outcome; this is unsurprising, since it is known that efficacy of PTNS seems to derive from something other than changes measurable by standard anorectal physiology parameters (7).
If not through changes in anorectal physiology, then how does PTNS improve FI? Our findings are also of interest given they help to deepen our understanding of the mechanisms of action, which are still not precisely understood. PTNS probably acts in a number of ways, but the mechanism that is most plausible is activation of somatic afferent fibers that, through activation of somato-visceral reflexes and modulation of sympathetic and parasympathetic neurons, inhibit colonic activity and enhance internal anal sphincter activity (29) . It is unclear whether this is via a spinal or supraspinal pathway; both may be involved. MS is a heterogeneous condition that can cause FI through a combination of factors, and one characterized by its very nature of having disseminated central nervous system lesions. Given that our cohort demonstrated a high rate of treatment success, across all subtypes, it fits in with the theory that PTNS works via activation of a number of somato-visceral reflexes, probably on both a spinal and supraspinal level. Focusing in particular on the possibility that the efficacy of PTNS is mediated by its effects on colonic motility, we also found that responders to PTNS were characterized by a significant improvement in stool consistency, supporting that hypothesis. This is conceivable, since by peripherally stimulating the sacral spinal cord, PTNS could cause reductions in colorectal motility and increase in intestinal transit time in a similar fashion to that already demonstrated by sacral neuromodulation (30, 31) . Stool consistency is not an outcome that has been assessed in other trials of PTNS. Our findings lend support to the hypothesis that improvements in stool consistency secondary to inhibition of colonic motility underlies at least some of the clinical efficacy of PTNS.
We acknowledge the lack of a control group in our study and the consequent failure to account for placebo response. However, the admittedly high placebo response rates in other sham-controlled trials of percutaneous PTNS have never been greater than around 30%, whether measured by reduction in FI episodes or by improvements in Wexner or quality of life scores (7, 32) . This implies that the effect size we described was more than could be attributed to a placebo effect. The data in this study provides the basis of a power calculation for a future definitive study. In addition, future studies could expand on our findings by examining long-term outcomes in this group of patients; we know that in non-neurogenic FI, durability of treatment response is reasonable, albeit often requiring "top-up" PTNS sessions (33, 34) .
In conclusion, this is the first study to describe the efficacy of PTNS in MS-related FI. The cohort as a whole exhibited a very high rate of treatment response (81%), and those with relapsing-remitting subtype did even better. Our findings suggest that PTNS is an effective tool for these patients, and also sheds light on its mechanism of action.
COMMENT
Patients suffering from multiple sclerosis often have progressive symptoms affecting bowel and bladder continence. Due to the centralized nature of MS, these symptoms represent the worst form of disease -one which affects both anatomy and physiology. The result is fecal incontinence that is refractory to many forms of medical therapy as these medications only temporize a portion of the physiologic disease at fault. Peripheral nerve stimulation is unique as a form of therapy with regards to this disease process; it is the one of very few tools available to the clinician which affects the anatomy and physiology concurrently.
Posterior tibial nerve stimulation (PTNS) has been proven to be effective for multiple forms of pelvic pathology in the past, specifically with regards to urinary issues (1) . Further, PTNS has been shown to improve urinary symptoms specifically in patients with MS (2-4). Similar logic holds that PTNS would improve fecal incontinence symptoms of MS patients in much the way that other forms of peripheral nervous stimulation (i.e. sacral nerve stimulation) have shown to improve these symptoms (5) .
The authors present a well-constructed manuscript with a significant number of MS patients undergoing PTNS for resolution of fecal incontinence. While traditionally a study with a small number of patients might be considered a weakness, this manuscript likely represents the largest sample size of MS patients to undergo PTNS that is currently available. The patient population does consist mostly of patients with relapsing-remitting MS, which one might argue would not be dissimilar from the overall patient population. The demyelinating nature of MS, however, means that patients with MS are far more likely than the overall population to develop FI (SPELL OUT) symptoms. It is useful to know that PTNS and other stimulatory techniques are of assistance in this difficult population and that these techniques are often able to improve the symptoms of patients with this disease. Of critical importance will be a follow up manuscript in about 2-3 years' time to see how patients have done following implantation, specifically focusing on patients that have developed more rapidly progressive MS over that interval.
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